Top

Published in:

Open Access 01-01-2008 | Preclinical Study

Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases

Authors: Ashish B. Rajput, Dmitry A. Turbin, Maggie CU Cheang, David K. Voduc, Sam Leung, Karen A. Gelmon, C. Blake Gilks, David G. Huntsman

Published in: Breast Cancer Research and Treatment | Issue 2/2008

Abstract

Purpose

We have previously demonstrated in a pilot study of 348 invasive breast cancers that mast cell (MC) infiltrates within primary breast cancers are associated with a good prognosis. Our aim was to verify this finding in a larger cohort of invasive breast cancer patients and examine the relationship between the presence of MCs and other clinical and pathological features.

Experimental design

Clinically annotated tissue microarrays (TMAs) containing 4,444 cases were constructed and stained with c-Kit (CD-117) using standard immunoperoxidase techniques to identify and quantify MCs. For statistical analysis, we applied a split-sample validation technique. Breast cancer specific survival was analyzed by Kaplan–Meier [KM] method and log rank test was used to compare survival curves.

Results

Survival analysis by KM method showed that the presence of stromal MCs was a favourable prognostic factor in the training set (P = 0.001), and the validation set group (P = 0.006). X-tile plot generated to define the optimal number of MCs showed that the presence of any number of stromal MCs predicted good prognosis. Multivariate analysis showed that the MC effect in the training set (Hazard ratio [HR] = 0.804, 95% Confidence interval [CI], 0.653–0.991, P = 0.041) and validation set analysis (HR = 0.846, 95% CI, 0.683–1.049, P = 0.128) was independent of age, tumor grade, tumor size, lymph node, ER and Her2 status.

Conclusions

This study concludes that stromal MC infiltration in invasive breast cancer is an independent good prognostic marker and reiterates the critical role of local inflammatory responses in breast cancer progression.

Baek JY, Tefferi A, Pardanani A, Li CY (2002) Immunohistochemical studies of c-kit, transforming growth factor-beta, and basic fibroblast growth factor in mast cell disease. Leuk Res 26:83–90PubMedCrossRef

Shijubo N, Kojima H, Nagata M, Ohchi T, Suzuki A, Abe S, Sato N (2003) Tumor angiogenesis of non-small cell lung cancer. Microsc Res Tech 60:186-198PubMedCrossRef

Ibaraki T, Muramatsu M, Takai S, Jin D, Maruyama H, Orino T, Katsumata T, Miyazaki M (2005) The relationship of tryptase- and chymase-positive mast cells to angiogenesis in stage I non-small cell lung cancer. Eur J Cardiothorac Surg 28:617–621PubMedCrossRef

Tataroglu C, Kargi A, Ozkal S, Esrefoglu N, Akkoclu A (2004) Association of macrophages, mast cells and eosinophil leukocytes with angiogenesis and tumor stage in non-small cell lung carcinomas (NSCLC). Lung Cancer 43:47–54PubMedCrossRef

Kankkunen JP, Harvima IT, Naukkarinen A (1997) Quantitative analysis of tryptase and chymase containing mast cells in benign and malignant breast lesions. Int J Cancer 72:385–388PubMedCrossRef

Lachter J, Stein M, Lichtig C, Eidelman S, Munichor M (1995) Mast cells in colorectal neoplasias and premalignant disorders. Dis Colon Rectum 38:290–293PubMedCrossRef

Yamamoto T, Katayama I, Nishioka K (1997) Expression of stem cell factor in basal cell carcinoma. Br J Dermatol 137:709–713PubMedCrossRef

Imada A, Shijubo N, Kojima H, Abe S (2000) Mast cells correlate with angiogenesis and poor outcome in stage I lung adenocarcinoma. Eur Respir 15:1087–1093CrossRef

Theoharides CT, Conti P (2004) Mast cells: the JEKYLL and HYDE of tumor growth. Trends Immunol 25:235–241PubMedCrossRef

10.

Ribatti D, Vacca A, Nico B, Crivellato E, Roncali L, Dammacco F (2001) The role of mast cells in tumour angiogenesis. Br J Haematol 115:514–521PubMedCrossRef

11.

Dabiri S, Huntsman D, Makretsov N, Cheang M, Gilks B, Bajdik C, Gelmon K, Chia S, Hayes M (2004) The presence of stromal mast cells identifies a subset of invasive breast cancers with a favourable prognosis. Mod Pathol 17:690–695PubMedCrossRef

12.

Aaltomaa S, Lipponen P, Papinaho S, Kosma VM (1993) Mast cells in breast cancer. Anticancer Res 13:785–788PubMed

13.

Chan JK, Loizzi V, Magistris A, Hunter MI, Rutgers J, DiSaia PJ, Berman ML (2005) Mast cell density, angiogenesis, blood clotting, and prognosis in women with advanced ovarian cancer. Gynecol Oncol 99:20–25PubMedCrossRef

14.

Tomita M, Matsuzaki Y, Onitsuka T (1999) Correlation between mast cells, survival rates in patients with pulmonary adenocarcinoma. Lung Cancer 26:103–108PubMedCrossRef

15.

Tan SY, Fan Y, Luo HS, Shen ZX, Guo Y, Zhao LJ (2005) Prognostic significance of cell infiltrations of immunosurveillance in colorectal cancer. World J Gastroenterol 11:1210–1214PubMed

16.

Burtin C, Ponvert C, Fray A, Scheinmann P, Lespinats G, Loridon B, Canu P, Paupe J (1985) Inverse correlation between tumor incidence and tissue histamine levels in W/WV, WV/+, and +/+ mice. J Natl Cancer Inst 74:671–674PubMed

17.

Olivotto IA, Bajdik CD, Ravdin PM, Speers CH, Coldman AJ, Norris BD, Davis GJ, Chia SK, Gelmon KA (2005) Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 23:2716–2725PubMedCrossRef

18.

Cheang MC, Treaba DO, Speers CH, Olivotto IA, Bajdik CD, Chia SK, Goldstein LC, Gelmon KA, Huntsman D, Gilks CB, Nielsen TO, Gown AM (2006) Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. J Clin Oncol 24:5637–5644PubMedCrossRef

19.

Liu CL, Prapong W, Natkunam Y, Alizadeh A, Montgomery K, Gilks CB, van de Rijn M (2002) Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays. Am J Pathol 161:1557–1565PubMed

20.

Camp RL, Dolled-Filhart M, Rimm DL (2004) X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 10:7252–7259PubMedCrossRef

21.

Bhowmick AN, Moses LH (2005) Tumor-stroma interactions. Curr Opin Genet Dev 15:97–101PubMedCrossRef

22.

West RB, Nuyten DS, Subramanian S, Nielsen TO, Corless CL, Rubin BP, Montgomery K, Zhu S, Patel R, Hernandez-Boussard T, Goldblum JR, Brown PO, van de Vijver M, van de Rijn M (2005) Determination of stromal signatures in breast carcinoma. PLoS Biol 3:e187PubMedCrossRef

23.

Ghiara P, Boraschi D, Villa L, Scapigliati G, Taddei C, Tagliabue (1985) In vitro generated mast cells express natural cytotoxicity against tumour cells. Immunology 55:317–324

24.

Welsh TJ, Green RH, Richardson D, Waller DA, O’Byrne KJ, Bradding P (2005) Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J Clin Oncol 23:8959–8967PubMedCrossRef

25.

Henderson WR, Chi EY, Jong EC, Klebanoff SJ (1981) Mast cell-mediated tumor-cell cytotoxicity. Role of the peroxidase system. J Exp Med 153:520–533PubMedCrossRef

26.

He S, Walls AF (1998) Human mast cell chymase induces the accumulation of neutrophils, eosinophils and other inflammatory cells in vivo. Br J Pharmacol 125:1491–1500PubMedCrossRef

27.

Vliagoftis H, Boucher WS, Mak LL, Theoharides CT (1992) Inhibition of mast cell secretion by oxidation products of natural polyamines. Biochem Pharmacol 43:2237–2245PubMedCrossRef

28.

Farram E, Nelson DS (1980) Mouse mast cells as anti-tumor effector cells. Cell Immunol 55:294–301PubMedCrossRef

29.

Latti S, Leskinen M, Shiota N, Wang Y, Kovanen PT, Lindstedt KA (2003) Mast cell-mediated apoptosis of endothelial cells in vitro: a paracrine mechanism involving TNF-alpha-mediated down-regulation of bcl-2 expression. J Cell Physiol 195:130–138PubMedCrossRef

30.

Kokenyesi R (2001) Ovarian carcinoma cells synthesize both chondroitin sulfate and heparan sulfate cell surface proteoglycans that mediate cell adhesion to interstitial matrix. J Cell Biochem 83:259–270PubMedCrossRef

31.

Johnson RJ, Couser WG, Alpers CE, Vissers M, Schulze M, Klebanoff SJ (1988) The human neutrophil serine proteinases, elastase and cathepsin G, can mediate glomerular injury in vivo. J Exp Med 168:1169–1174PubMedCrossRef

32.

Schick C, Kamachi Y, Bartuski AJ, Cataltepe S, Schechter NM, Pemberton PA, Silverman GA (1997) Squamous cell carcinoma antigen 2 is a novel serpin that inhibits the chymotrypsin-like proteinases cathepsin G and mast cell chymase. J Biol Chem 272:1849–1855PubMedCrossRef

33.

Hara M, Matsumori A, Ono K, Kido H, Hwang MW, Miyamoto T, Iwasaki A, Okada M, Nakatani K, Sasayama S (1999) Mast cells cause apoptosis of cardiomyocytes and proliferation of other intramyocardial cells in vitro. Circulation 100:1443–1449PubMed

34.

Leskinen MJ, Lindstedt KA, Wang Y, Kovanen PT (2003) Mast cell chymase induces smooth muscle cell apoptosis by a mechanism involving fibronectin degradation and disruption of focal adhesions. Arterioscler Thromb Vasc Biol 23:238–243PubMedCrossRef

35.

Ruoss SJ, Hartmann T, Caughey GH (1991) Mast cell tryptase is a mitogen for cultured fibroblasts. J Clin Invest 88:493–499PubMedCrossRef

36.

Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942–949PubMedCrossRef

37.

Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D, Zhang A, Dahm P, Chao N, Gilboa E, Vieweg J (2005) Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 115:3623–3633PubMedCrossRef

38.

Farinha P, Masoudi H, Skinnider BF, Shumansky K, Spinelli JJ, Gill K, Klasa R, Voss N, Connors JM, Gascoyne RD (2005) Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 106:2169–2174PubMedCrossRef

39.

Pollard JW (2004) Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4:71–78PubMedCrossRef

40.

Bellocq A, Antoine M, Flahault A, Philippe C, Crestani B, Bernaudin JF, Mayaud C, Milleron B, Baud L, Cadranel J (1998) Neutrophil alveolitis in bronchioloalveolar carcinoma: induction by tumor-derived interleukin-8 and relation to clinical outcome. Am J Pathol 152:83–92PubMed

41.

Caruso RA, Bellocco R, Pagano M, Bertoli G, Rigoli L, Inferrera C (2002) Prognostic value of intratumoral neutrophils in advanced gastric carcinoma in a high-risk area in northern Italy. Mod Pathol 15:831–837PubMedCrossRef

42.

Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960–1964PubMedCrossRef

Title: Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases
Authors: Ashish B. Rajput
Dmitry A. Turbin
Maggie CU Cheang
David K. Voduc
Sam Leung
Karen A. Gelmon
C. Blake Gilks
David G. Huntsman
Publication date: 01-01-2008
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2008
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-007-9546-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Experimental design

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2008

Diminished feedback regulation of proteasome expression and resistance to proteasome inhibitors in breast cancer cells

A randomized controlled trial of a decision aid for women considering genetic testing for breast and ovarian cancer risk

Insulin-like growth factor binding proteins and breast cancer

Exploring the two-gene ratio in breast cancer—independent roles for HOXB13 and IL17BR in prediction of clinical outcome

Prophylactic IL-12 treatment reduces postoperative metastasis: mediation by increased numbers but not cytotoxicity of NK cells

Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer